Aerolase, a global technology leader in laser skin health, has taken a significant step forward in the Indian market with the launch of its US FDA-approved Neo Elite laser treatment in collaboration with Kaya, a leading dermatology chain clinic in India.
The treatment will now be available across all Kaya clinics nationwide, signifying a major leap forward in non-invasive skincare for Indian consumers. As a pioneer in global skincare innovation, Aerolase is empowering Indian consumers by making advanced, research-driven treatments available and customisable for the diverse needs of Indian skin.
Acne is one of the most common dermatologic conditions worldwide, with a global prevalence estimated at approximately 9–10% based on Global Burden of Disease (GBD) data. Traditional acne treatments, oral medications, creams, and hormone therapies require prolonged use. This has led to the rise in demand for non-invasive, effective solutions with minimal or no downtime and discomfort.
Underscoring the market need for this innovation, voiced Madhusudhan HK, Country Manager, Aerolase, "India’s dermatology and aesthetic market is among the fastest-growing globally, projected to grow at a CAGR of 10.11% from 2025 to 2032. Aerolase’s collaboration with Kaya is perfectly timed to meet India’s rising demand by innovations such as 650 microsecond breakthrough technology for safer, customisable treatments. Within this rapidly advancing landscape, Neo Elite’s technology stands out by not overheating surrounding skin or causing pigmentation issues. Its contactless design ensures optimal hygiene, making it ideal for those with acne-prone skin. The device effectively addresses active acne, post-inflammatory hyperpigmentation, and redness in the same session, minimizing the need for multiple treatments. Its versatility means it can treat a range of concerns, from teenage Acne to adult acne and postpartum breakouts, and can be safely integrated with existing skincare routines.”
Aerolase has collaborated with Kaya to bring its advanced laser technology to a broader patient base. Supported by extensive global clinical evidence, Aerolase offers reliable, reproducible outcomes across 36 indications from aesthetic procedures to complex dermatological conditions. By integrating with Kaya’s wide-ranging expertise, the collaboration aims to enhance access to comprehensive, science-driven skin and beauty solutions.
